ESC Professional Premium Access

Effect of sodium-related glucose transporter 2 -Inhibitors on exercise capacity in heart failure patients with reduced ejection fraction, does etiology matter?

Congress Presentation

About the speaker

Mr Emanuele Coppo

General Hospital of Jerez, Jerez de la Frontera (Spain)
0 follower

5 more presentations in this session

The effect of sglt-2 inhibitor dapagliflozin on adropin serum levels in patients with chronic heart failure and concomitant type 2 diabetes mellitus

Speaker: Professor A. Berezin (Salzburg, AT)

Thumbnail

Uptake of SGLT2i therapy among patients hospitalized with heart failure: Insights from the veterans affairs healthcare system

Speaker: Doctor A. Varshney (Palo Alto, US)

Thumbnail

Efficacy of dapagliflozin according to geographic regions in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER

Speaker: Doctor T. Kondo (Glasgow, GB)

Thumbnail

Sodium-glucose cotransporter inhibitors reduce cardiovascular outcomes regardless eGFR range in patients with heart failure. Systematic review and meta-regression meta-analysis

Speaker: Doctor I. Cunha (Sao Paulo, BR)

Thumbnail

Prognostic implications of angiopoietin-2 in heart failure and the influence of empagliflozin: the EMPEROR program

Speaker: Professor J. Butler (Dallas, US)

Thumbnail

Access the full session

More insights into SGLT2i in heart failure

Speakers: Mr E. Coppo, Professor A. Berezin, Doctor A. Varshney, Doctor T. Kondo, Doctor I. Cunha...
Thumbnail

About the event

Image

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

ESC 365 is supported by